InflaRx (IFRX) AI Stock Analysis

• Market Cap: $60.42M
• Dividend Yield: N/A
• Average Volume (3M): 375.02K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.97
• Revenue Growth: 178.84%
• EPS Growth: -40.60%
• Country: US
• Employees: 74
• Sector: Healthcare
• Sector Strength: 70
• Industry: Biotechnology
• EPS (TTM): -1.05
• Shares Outstanding: 67,133,270
• 10 Day Avg. Volume: 446,737
• 30 Day Avg. Volume: 375,018
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 1094.58
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $7.67
• Price Target Upside: 733.70% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

InflaRx's overall stock score is low due to significant financial challenges, including negative profitability and cash flow issues. The technical analysis also suggests bearish momentum, with the stock trading below key moving averages and indicators pointing to oversold conditions. The negative P/E ratio and absence of a dividend further impact the valuation negatively.

Positive Factors

Financial Stability

The company is funded into 2027, providing strong financial stability for future developments.

Market Opportunity

PG has no approved drugs in Europe or in the U.S., indicating a potential market opportunity.

Regulatory Approvals

Gohibic previously received FDA Fast Track Designation for the treatment of PG and has Orphan Drug Designation for PG from the FDA and EMA.

Negative Factors

Clinical Trial Results

Gohibic in the Phase 2b SHINE trial for hidradenitis suppurativa did not meet the primary endpoint.

Trial Uncertainty

The interim analysis will determine whether the trial sample size will be adapted or whether the trial should be stopped due to futility, which is a crucial step in the study's progress.

InflaRx Business Overview & Revenue Model

Company Description

InflaRx (IFRX) is a clinical-stage biopharmaceutical company focused on discovering and developing anti-inflammatory therapeutics by targeting the complement system. The company's core product, vilobelimab, is a monoclonal anti-C5a antibody that aims to treat a variety of inflammatory conditions and autoimmune diseases. InflaRx operates primarily in the biotechnology and pharmaceutical sectors, striving to provide innovative treatment options for patients suffering from severe and life-threatening inflammatory diseases.

How the Company Makes Money

InflaRx generates revenue primarily through partnerships and collaboration agreements with other pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments based on development and regulatory achievements, and royalties on sales if products reach commercialization. Additionally, InflaRx may receive research and development grants or funding from governmental or non-governmental organizations to support its clinical trials and drug development programs. The company's revenue model is heavily dependent on the successful clinical development and eventual commercialization of its lead product candidate, vilobelimab, as well as potential future products.

InflaRx Financial Statement Overview

Summary

InflaRx's financials reflect significant operational and financial challenges. The company struggles with profitability and cash flow management, evident from negative margins and consistent cash outflows. While the balance sheet shows limited leverage, negative returns and persistent losses are concerning for future financial stability.

Income Statement

InflaRx's income statement shows significant challenges in profitability and revenue growth. The company has been operating at a loss with negative net income and gross profit margins. Although total revenue increased from 2023 to 2024, the net profit margin remains negative, reflecting continued financial strain.

Balance Sheet

The balance sheet highlights high equity levels relative to debt, but the company has been operating with net debt positions, suggesting better liquidity management. However, the return on equity is negative due to persistent net losses, pointing to concerns in generating returns for shareholders.

Cash Flow

InflaRx's cash flow statement indicates consistent negative operating cash flow and free cash flow, suggesting ongoing cash burn issues. The free cash flow to net income ratio is poor, pointing to challenges in converting earnings into cash.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
165.79K	63.09K	0.00	0.00	0.00
	Gross Profit
-3.15M	-469.17K	-585.85K	-696.14K	-664.03K
	EBIT
-53.01M	-44.91M	-32.24M	-47.63M	-33.94M
	EBITDA
-45.55M	-42.06M	-31.29M	-46.90M	-32.47M
	Net Income Common Stockholders
-46.06M	-42.67M	-27.04M	-45.65M	-34.01M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
52.84M	90.27M	81.81M	83.41M	81.13M
	Total Assets
76.02M	120.21M	102.40M	125.14M	88.22M
	Total Debt
805.09K	1.12M	1.36M	1.43M	559.04K
	Net Debt
-17.57M	-11.65M	-14.91M	-24.82M	-25.41M
	Total Liabilities
14.60M	17.63M	14.05M	19.86M	10.35M
	Stockholders Equity
61.42M	102.67M	88.35M	105.28M	77.86M
Cash Flow		Free Cash Flow
-48.60M	-37.89M	-33.91M	-39.97M	-36.62M
	Operating Cash Flow
-48.56M	-37.81M	-33.74M	-39.94M	-36.53M
	Investing Cash Flow
52.36M	-17.70M	19.36M	-25.95M	21.36M
	Financing Cash Flow
386.45K	52.99M	1.94M	61.58M	9.17M

InflaRx Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.92
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IFRX, the sentiment is Negative. The current price of 0.92 is below the 20-day moving average (MA) of 1.14, below the 50-day MA of 1.56, and below the 200-day MA of 1.74, indicating a bearish trend. The MACD of -0.15 indicates Negative momentum. The RSI at 31.57 is Neutral, neither overbought nor oversold. The STOCH value of 4.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IFRX.

InflaRx Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMGN	75 Outperform	$156.37B	38.50	67.55%	3.24%	18.64%	-39.39%
BIIB	65 Neutral	$16.60B	10.30	10.36%	―	-1.60%	39.71%
VRTX	64 Neutral	$122.24B	―	-3.15%	―	11.64%	-114.72%
IONS	49 Neutral	$4.25B	―	-93.03%	―	-10.48%	-18.79%
Sector *	48 Neutral	$6.25B	1.14	-46.26%	2.69%	19.24%	1.75%
RARE	47 Neutral	$3.11B	―	-214.50%	―	29.01%	23.93%
IFRX	35 Underperform	$60.42M	―	-62.38%	―	178.84%	-40.60%